Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Train crash in India kills more than 260 people
    • Saudi Arabia’s ‘prickly prince’ of oil bristles as crude price slides
    • CIA chief made secret trip to China in bid to thaw relations
    • US defence chief warns China against risky behaviour in Indo-Pacific
    • Indonesia floats Ukraine peace plan, triggering sharp western criticism
  • UK
    Sections
    • UK Home
    • UK Business & Economy
    • UK Politics & Policy
    • Brexit
    • UK Companies
    • Personal Finance
    Most Read
    • Somerset’s ‘smelly town’ sets its sights on UK’s biggest gigafactory for revival
    • UK medical cannabis group woos patients to buy into the business
    • Why Britain’s households should expect energy bills to remain high
    • Rishi Sunak warned not to enter car ‘subsidy race’ with US and EU
    • UK offers £1,500 payment to civil servants in bid to end strikes
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Six Glazer siblings could retain Manchester United stakes under Ratcliffe offer
    • More than 400 Grail patients incorrectly told they may have cancer
    • AI ripe to shake up private banking, says Israeli entrepreneur
    • Airline orders point to resurgent post-pandemic travel demand
    • ‘Everyone will get affected’: Tesla jolts EV charging industry
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    Most Read
    • Saudi Arabia’s ‘prickly prince’ of oil bristles as crude price slides
    • Handful of tech stocks drive diverging measures of S&P 500 performance
    • Active management is a sham — no wonder my returns are suspect
    • ‘There needs to be a health warning’: How crypto trading can lead to addiction
    • Inflation back at the top of the fear list for worrywart investors
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Management 101: don’t drain a reservoir to find your phone
    • AI has given Palantir its mystique back
    • The frictionless life goes on
    • Active management is a sham — no wonder my returns are suspect
    • Will ChatGPT be Homer Simpson’s salvation?
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • ‘Everyone has the right to completely log off’: what bosses think about the right to disconnect
    • Wellcome Leap’s Regina Dugan: ‘Odds are irrelevant, if what you’re trying to do is important’
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Cristiano Ronaldo vs Lionel Messi: who was the greatest footballer?
    • Sci-fi writer Ted Chiang: ‘The machines we have now are not conscious’
    • Why motorcycle gangs will end with a whimper, not a rev
    • Trump or not, US meltdown could be inevitable
    • The American luxury lifestyle brand storming the Cotswolds
  • HTSI
MenuSearch
  • Home
  • World
  • UK
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Covid-19 vaccines

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Friday, 26 May, 2023
    Brussels and Pfizer agree deal to cut supply of Covid vaccines

    Revised contract addresses concerns over costly glut of unwanted shots as public health threat wanes

  • Sunday, 14 May, 2023
    Novavax Inc
    Cash-strapped Novavax urges governments to honour Covid jab deals

    US biotech group is among coronavirus vaccine makers struggling with reduced demand post-pandemic

  • Friday, 12 May, 2023
    Simon Schama
    The thwarting of science will always be a human failing

    From India to Britain, we have always managed to get in the way of our own inventiveness

  • Tuesday, 9 May, 2023
    Janan Ganesh
    The west’s handling of the pandemic beat its own expectations

    A demonised elite produced vaccines and furloughs while a supposedly rebellious public mostly followed the rules

  • Monday, 1 May, 2023
    Noubar Afeyan
    Moderna co-founder calls on US politicians and judges to stop questioning science

    Noubar Afeyan says court rulings on abortion pills and access to healthcare undermine efforts to combat diseases

  • Sunday, 30 April, 2023
    BioNTech/Pfizer’s mooted EU deal for 70mn Covid shots threatens rivals

    European health officials have advocated portfolio diversity to help fight different variants

  • Friday, 28 April, 2023
    Special ReportThe Americas’ Fastest Growing Companies
    Moderna tries to show it’s not a ‘one trick pony’

    Covid vaccine maker is sitting on $18bn and embarking on a host of ambitious projects

  • Wednesday, 26 April, 2023
    Pharmaceuticals sector
    EU aims to create ‘single market for medicines’ with overhaul of pharma rules

    Revamp that would cut drugmakers’ years of market exclusivity meets fierce opposition from sector

  • Monday, 24 April, 2023
    EU business regulation
    EU outlines plan to take control of medicine production in health crises

    Proposal for compulsory licensing risks ire of pharma groups keen to protect patents and revenue

  • Monday, 27 March, 2023
    BioNTech
    BioNTech forecasts slump in sales as demand for Covid jab wanes

    Expected fall highlights challenges for pharmaceutical companies that experienced pandemic windfall

  • Wednesday, 15 March, 2023
    Taiwan
    Taiwan loses diplomatic ally as Honduras confirms link to China

    Central American nation was one of Taipei’s last partners in Washington’s backyard

  • Tuesday, 14 March, 2023
    Pfizer’s revised EU Covid vaccine contract meets resistance

    Four member states including Poland say amended deal is not ‘fair solution’ to surplus of shots

  • Tuesday, 7 March, 2023
    UK spring Covid boosters will target elderly and vulnerable

    Health secretary confirms acceptance of advice from expert committee to ‘bridge the gap’ to autumn

  • Wednesday, 15 February, 2023
    CanSino says vaccine demand down after China’s mass Covid infections

    Pharma group hopes for approval of mRNA vaccine for booster shots

  • Sunday, 29 January, 2023
    Drugs research
    RQ Bio partners with AstraZeneca in Covid antibody fight

    UK biotech racing to keep antibody up to date with latest variants

  • Tuesday, 10 January, 2023
    Chinese bank tries to entice wealthy customers with mRNA vaccines

    Hong Kong-based lender seeks to cater to mainlanders’ demand for western jabs

  • Monday, 9 January, 2023
    CureVac GmbH
    Covid vaccine makers CureVac and Novavax appoint new chiefs

    Pharmaceutical groups to part ways with longstanding executives

  • Monday, 9 January, 2023
    InterviewPharmaceuticals sector
    SK Bioscience says ‘national pride’ prevents China from accepting foreign Covid jabs

    South Korean vaccine maker looks elsewhere to expand overseas business

  • Friday, 6 January, 2023
    New Chinese mRNA Covid vaccine shows positive early results

    Jab developed by CanSinoBio could help nation grappling with a wave of infection

  • Thursday, 5 January, 2023
    ExplainerCoronavirus
    How serious is the threat of new Covid-19 variants?

    A surge in cases after China lifted restrictions has sparked concerns that a dangerous new strain could emerge

  • Tuesday, 3 January, 2023
    EU offers free Covid-19 vaccines to China to help curb outbreak

    Beijing rejects Brussels’ offer, citing full control of situation

  • Monday, 26 December, 2022
    Chinese society
    Chinese vaccine tourists flock to Macau for mRNA Covid jabs

    Explosion of cases and ban on more effective western shots lead residents to look abroad

  • Monday, 12 December, 2022
    China warned to accelerate approval of updated jabs to tackle Covid ‘tsunami’

    Authorities have relied on vaccines made using original strain found in Wuhan

  • Wednesday, 7 December, 2022
    Coronavirus
    China risks ‘wave of infections’ after relaxing zero-Covid policy, warns Fauci

    Joe Biden’s chief medical adviser urges Beijing to approve use of western vaccines

  • Tuesday, 6 December, 2022
    News in-depthChinese politics & policy
    China’s elderly vaccine refuseniks pose obstacle for Xi Jinping

    Nearly 90mn Chinese are insufficiently protected against Covid as Beijing begins to unwind pandemic controls

Previous page You are on page 1 Next page

Recommended

Covid-19 vaccine tracker: Lowest-income countries lag further behind rest of the world
Covid vaccine development: The shots available and the doses administered
In graphics: the UK vaccine supply chain
Coronavirus: free to read
Coronavirus tracker: the latest figures as countries fight the Covid-19 resurgence

Be part of FT Community

Discover unmissable flagship events and members only communities to expand your thinking and elevate your career

FT Live
Global Pharma and Biotech Summit
Driving Investment and Innovation in Life Sciences
Tuesday, 7th NovemberUK & Online
Learn more about FT Community

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsFT Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

UK Edition

Subscribe for full access
  • Switch to International Edition

Top sections

  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • UK
    • UK Business & Economy
    • UK Politics & Policy
    • Brexit
    • UK Companies
    • Personal Finance
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports

FT recommends

  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Live Events
  • FT Forums
  • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In